

Press Release
05 September 2022 15:00:00 CEST



Newbury Pharmaceuticals engages Pareto Securities to reduce spread in share price

Newbury Pharmaceuticals has entered into an agreement with Pareto Securities whereby Pareto Securities will act as liquidity provider for the Newbury share. The assignment takes place within the framework of Nasdaq First North Growth Market's liquidity provision rules and means that the liquidity provider quotes a buy and sell volume corresponding to at least SEK 15,000, with a maximum spread of 4% between the bid and ask price. The purpose is to promote the share's liquidity, and the assignment commences on Tuesday, September 6th, 2022.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury Pharmaceuticals engages Pareto Securities to reduce spread in share price](#)